Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs.

Drug metabolism and disposition: the biological fate of chemicals - 1 Sept 2021

Pike Andy, Jones Barry, Markandu Roshini, O'Neill Daniel

Abstract excerpt

Inconsistencies in pharmacokinetic parameters between individual animals in preclinical studies are a common occurrence. Often such differences between animals are simply accepted as experimental variability rather than as indications of specific differences in animal phenotype that could lead to a different interpretation of the data. The fraction unbound in plasma is one factor influencing pharmacokinetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Proteins
Share to Dogs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Development

Share to Enzyme Inhibitors

Share to Metabolic Clearance Rate

Share to Orosomucoid

Share to Pharmacogenomic Variants

Share to Syk Kinase

Source

Identifiers

PMID: 34135088
DOI: 10.1124/dmd.121.000409

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Interindividual Differences in Plasma Fraction Unbound on the Pharmacokinetics of a Novel Syk Kinase Inhibitor in Beagle Dogs.PMID 34135088Read ↗

Canine orosomucoid (alpha-1 acid glycoprotein) variants and their influence on drug plasma protein binding.Semantic proximity Read ↗

Interindividual pharmacokinetics variability of the alpha(4)beta(1) integrin antagonist, 4-[1-[3-chloro-4-[N'-(2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidine-2-yl]methoxybenzoic acid (D01-4582), in beagles is associated with albumin genetic polymorphisms.Semantic proximity Read ↗

Implications of ABC transporters on the disposition of typical veterinary medicinal products.Semantic proximity Read ↗

Identification of the novel canine CYP1A2 1117 C > T SNP causing protein deletion.Semantic proximity Read ↗

Phenacetin pharmacokinetics in CYP1A2-deficient beagle dogs.Semantic proximity Read ↗

Population variability in animal health: Influence on dose-exposure-response relationships: Part I: Drug metabolism and transporter systems.Semantic proximity Read ↗

Tolerance and Pharmacokinetics of Galliprant™ Administered Orally to Collies Homozygous for MDR1-1Δ.Semantic proximity Read ↗

Oral bioavailability of P-glycoprotein substrate drugs do not differ between ABCB1-1Δ and ABCB1 wild type dogs.Semantic proximity Read ↗

Understanding Inter-Individual Variability in Monoclonal Antibody DispositionSemantic proximity Read ↗

The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor.Semantic proximity Read ↗

Impact of ABCB1 genotype in Collies on the pharmacokinetics of R- and S-fexofenadine.Semantic proximity Read ↗

In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.